Aim: Recently approved for use in complicated intra-abdominal infection, eravacycline is a
novel fluorocycline with broad spectrum of activity against resistant Gram-negative …

Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core
scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in …

Background Increasing antimicrobial resistance among pathogens that cause complicated
intraabdominal infections (cIAIs) supports the development of new antimicrobials …

Eravacycline is a novel fluorocycline, highly active against Gram-positive and Gram-
negative pathogens in vitro, including those with tetracycline and multidrug resistance. This …

Complicated intra-abdominal infections (cIAIs) are commonly associated with
multimicroorganisms and treatment choices are becoming narrower due to developing …

Objectives Eravacycline is a novel, fully-synthetic tetracycline approved by the FDA for
treatment of complicated intra-abdominal infections in August 2018. This study sought to …

Importance Eravacycline is a novel, fully synthetic fluorocycline antibiotic of the tetracycline
class with in vitro activity against clinically important gram-negative, gram-positive aerobic …

Introduction: Complicated intra-abdominal infections (cIAIs) are among the most frequent
infections, contributing to significant morbidity and healthcare costs. Several medical needs …

Introduction: There has been a dramatic increase in the incidence of multidrug-resistant
pathogens over the past few years, which highlights the need for new anti-infective …

Eravacycline is an investigational, synthetic fluorocycline antibacterial agent that is
structurally similar to tigecycline with two modifications to the D-ring of its tetracycline core: a …